[PDF][PDF] Efficacy of cetuximab combined with chemotherapy in 53 patients with advanced colorectal cancer
GF Guo, LP Xia, B Zhang, WQ Jiang, MZ Liu… - Chinese J …, 2009 - scholar.archive.org
… suggested that the epidermal growth factor receptor … clinical studies with cetuximab as
secondline treatment or above. In recent years, there were also multicenter studies with cetuximab …
secondline treatment or above. In recent years, there were also multicenter studies with cetuximab …
[PDF][PDF] 西妥昔单抗联合化疗或放疗治疗晚期头颈鳞癌的疗效评价
李金忠， 郑家伟， 张志愿 - 上海口腔医学, 2008 - sjos.cn
… Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and
cisplatin for recurrent and refractory … Phase I study of antiNN epidermal growth factor receptor …
cisplatin for recurrent and refractory … Phase I study of antiNN epidermal growth factor receptor …
HER2 阳性结直肠癌研究进展
祁雅丽， 苟亚妮， 达丽隽， 李恩喜， 刘雅婷， 裴霞霞… - 肿瘤防治研究, 2023 - zlfzyj.com
… of epidermal growth factor receptor monoclonal antibodies. With … EGFR/HER2 mutant
advanced solid tumor Phase 2 … as an effective therapeutic target in cetuximab-resistant colorectal …
advanced solid tumor Phase 2 … as an effective therapeutic target in cetuximab-resistant colorectal …
以表皮生长因子受体为靶点的肿瘤分子靶向治疗
郑玉民， 王自正， 王峰， 范我 - 国际放射医学核医学杂志, 2007 - ijrmnm.com
… Cetuximab, a monor clonal antibody targeting the epidermal growth factor receptor, in
combination … pancreatic cancer: a multicenter phase II Trial. J Clin Oncol, 2004, 22(13): …
combination … pancreatic cancer: a multicenter phase II Trial. J Clin Oncol, 2004, 22(13): …
[PDF][PDF] 晚期口腔颌面-头颈部鳞癌靶向治疗的进展浅析
郭伟 - 口腔颌面外科杂志, 2012 - journal06.magtech.org.cn
… 结构有表皮生长因子受体 (epidermal growth factor receptor, EGFR),血管内皮 生长… Phase II
multicenter study of the antiepidermal growth factor receptor monor clonal antibody cetuximab …
multicenter study of the antiepidermal growth factor receptor monor clonal antibody cetuximab …
西妥昔单抗在转移性结直肠癌一线治疗后的后续应用研究进展
吴佳， 周嘉梁 - 中国癌症杂志, 2020 - china-oncology.com
… 因子受体2(human epidermal growth factor receptor 2,HER2)… 内皮生长因子2(vascular
endothelial growth factor 2,VEGF2),… line cetuximab and irinotecan: a phase 2 single-arm clinical …
endothelial growth factor 2,VEGF2),… line cetuximab and irinotecan: a phase 2 single-arm clinical …
[HTML][HTML] EGFR 抑制剂在胃癌中的研究进展
涂金花， 余英豪 - 世界华人消化杂志, 2011 - wjgnet.com
… 表皮生长因子受体(epidermal growth factor receptor, EGFR)信号转导通路在胃癌细胞的增殖
,… 最近Han等[11]在研究胃癌患者EGFR基因遗传多态性与西妥昔单抗(cetuximab)单独及其联合…
,… 最近Han等[11]在研究胃癌患者EGFR基因遗传多态性与西妥昔单抗(cetuximab)单独及其联合…
[HTML][HTML] 转化生长因子α (TGF-α) 在肿瘤治疗中的应用现状及展望
韩祺蕾， 李凯 - 复旦学报(医学版), 2019 - jms.fudan.edu.cn
… growth factor (EGF) family, which is capable of specifically binding to epidermal growth factor
receptor (EGFR… Influence of the HER receptor ligand system on sensitivity to cetuximab and …
receptor (EGFR… Influence of the HER receptor ligand system on sensitivity to cetuximab and …
抗EGFR 单抗治疗复发/转移性头颈部鳞状细胞癌临床共识(2021 年版)
郭晔， 张陈平 - 中国癌症杂志, 2021 - china-oncology.com
… 表皮生长因子受体(epidermal growth factor receptor,EGFR), 因此… A randomized, phase 2
study of cetuximab plus cisplatin with … Phase Ⅱ multicenter study of the epidermal growth factor …
study of cetuximab plus cisplatin with … Phase Ⅱ multicenter study of the epidermal growth factor …
RAS 野生型转移性结直肠癌EGFR 抑制剂耐药机制的研究进展
俞悦， 周爱萍 - 中国肿瘤临床, 2017 - cjco.cn
… 摘要抗表皮生长因子受体(epidermal growth factor receptor,… to the EGFR-directed therapeutic
antibody cetuximab[J]. Sci … including ERBB2/HER2 in a phase II study of KRAS wild-type …
antibody cetuximab[J]. Sci … including ERBB2/HER2 in a phase II study of KRAS wild-type …